United Kingdom· GB-APID-38705911000001102
Fetcroja 1g powder for concentrate for solution for infusion vials
A cefiderocol product containing cefiderocol, registered in United Kingdom by Shionogi BV. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Cefiderocol is registered in 13 of 19 countries.
Countries holding a registration under ATC J01DI04 (cefiderocol), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Cefiderocol · ATC J01DI04
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Cefiderocol
- Manufacturer
- Shionogi BV
- Country
- United Kingdom (GB)
- ATC code
- J01DI04
- ATC class
- Cefiderocol
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05060431940172
- gtin5060431940172
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for cefiderocol.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cefiderocol · interactions on record
22 records
- 5 severe
- 17 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- HydrocodoneR05DA03severe
- IohexolV08AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cefiderocol in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFETCROJAShionogi B.V., Amsterdam
- SpainFETCROJA 1 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONShionogi B.V.
- FinlandFetcrojaShionogi B.V.
- FranceFETCROJA 1 g, poudre pour solution à diluer pour perfusionSHIONOGI (PAYS BAS)
- IrelandFetcroja 1 g powder for concentrate for solution for infusionShionogi B.V.
- IcelandFetcrojaShionogi B.V.
- NetherlandsFetcroja 1 g, poeder voor concentraat voor oplossing voor infusieShionogi B.V.
- NorwayFetcrojaShionogi B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Fetcroja
- Liechtenstein · Fetcroja
- Norway · Fetcroja
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2896e70e-5e79-4099-8a52-7f70c6bd5763 GET /v1/drugs/2896e70e-5e79-4099-8a52-7f70c6bd5763?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38705911000001102",
"desc": "Fetcroja 1g powder for concentrate for solution for infusion vials (Shionogi BV)",
"form": "Powder for solution for infusion",
"vpid": "39002611000001100",
"source": "dmd",
"vtm_id": "830205006",
"strength": "1 gram",
"substance": "Cefiderocol",
"ingredient": "Cefiderocol sulfate tosylate",
"supplier_code": "35587611000001105"
}See everything about cefiderocol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.